**Phase 3 Trial in Progress: Tislelizumab Plus Cisplatin/Carboplatin and Gemcitabine Versus Placebo Plus Cisplatin/Carboplatin and Gemcitabine in Chinese Patients With Advanced Urothelial Carcinoma**

Feng Bi1, Han-Zhong Li2, Shaoxing Zhu3, Qing Zou4, Jia Tang5, Wei Zhang5, Ding-Wei Ye6

1West China Hospital, Sichuan University, Sichuan, China; 2Peking Union Medical College Hospital, Beijing, China; 3Zhejiang Cancer Hospital, Hangzhou, China; 4Jiangsu Cancer Hospital, Jiangsu, China; 5BeiGene (Shanghai) Co., Ltd., Shanghai, China; 6Fudan University Shanghai Cancer Center, Shanghai, China

**Background:** Combining anti-PD-1 treatment with platinum-based chemotherapy may have synergistic effects and has demonstrated antitumor activity in a variety of tumor types. Tislelizumab is a clinical-stage monoclonal antibody with high affinity and specificity for PD-1 engineered to minimize binding to FcγR on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. Previous reports showed single-agent tislelizumab was generally well tolerated and had antitumor activity in patients with locally advanced/metastatic urothelial carcinoma (UC). Tislelizumab was recently approved in China for the treatment of patients with PD-L1-high locally advanced/metastatic UC who have progressed during/after platinum chemotherapy.

**Methods:** This phase 3, randomized, double-blind, placebo-controlled study (NCT03967977) will compare the efficacy and safety/tolerability of tislelizumab vs placebo, both in combination with cisplatin/carboplatin and gemcitabine. Adult Chinese patients (n=420) with histologically confirmed, inoperable, locally advanced/metastatic UC who are eligible for (but have not received) systemic anticancer therapy for advanced UC, therapies targeting PD-1/L1, or other antibodies/drugs targeting T-cell co-stimulation or checkpoint pathways are eligible. Enrolled patients will be randomized 1:1 to receive tislelizumab (200 mg Q3W) or placebo (Q3W) plus gemcitabine (1000 mg/m² administered on Day 1 and 8 of each 3-week cycle) and cisplatin (70 mg/m²) or carboplatin (AUC 4.5) administered on Day 1 or 2 of each 3-week cycle. Patients must provide a fresh biopsy or archival tissue for central assessment of PD-L1 expression. Overall survival (OS) is the primary endpoint. Investigator-assessed overall response rate (RECIST v1.1), duration of response, progression-free survival, and OS rates at Year 1 and 2 are secondary endpoints. Safety/tolerability, assessed by monitoring incidence and severity of adverse events, and health-related quality-of-life measures will also be evaluated.